Floatz logo

PALMITIC MONOETHANOLAMIDE

Headache, Migraine

RDC Clinical Pty LtdSmall moleculePhase 3Active
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
56/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Headache, Migraine cohort.

Asset / SponsorPhaseRating
Haloperidol
Western Michigan University School of Medicine
Phase 4BB
ORSYTHIA COMPONENT ETHINYL ESTRADIOL
Leiden University Medical Center
Phase 3BB
INDOMETACINUM
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Phase 4BB
BGC-20-1531
Danish Headache Center
Phase 2B
(D)-LIMONENE
Pure Green
Phase 2CCC

View all 17 →

Same molecule, other indications

PALMITIC MONOETHANOLAMIDE is also rated in:

chronic prostatitisDormant
BB
Indicative ·
69 / 100
View asset →
Chronic Prostatitis With Chronic Pelvic Pain SyndromeDormant
BB
Indicative ·
69 / 100
View asset →
chronic pain syndromeDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →